23 results on '"Perol, M."'
Search Results
2. P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial.
3. PL02.05 IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab.
4. 186TiP An open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
5. OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01.
6. FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
7. MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01.
8. 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC).
9. 168P: Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study.
10. VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data.
11. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
12. Embolie gazeuse de révélation tardive après ponction transpariétale pulmonaire
13. O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer
14. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study
15. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer: GFPC 99-01 study (Groupe français de pneumo-cancérologie)
16. PCN153 - Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France.
17. PCN147 - Is the Integrated Electronic Health Record Cost-Effective for a Cancer Consultation? Results from the E-SI (PREPS-SIPS) Study.
18. Ré-irradiation des tumeurs thoraciques par CyberKnife® : faisabilité et tolérance.
19. Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer.
20. 9005 ORAL Is There a Benefit to Maintenance Therapy After First Line Chemotherapy in Advanced Non-small Cell Lung Cancer – a Systematic Review With Meta-analysis
21. P-941 Phase II study of gefitinib (IRESSA) administered as first linetreatment in patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC)
22. P-479 Expression of class III beta tubulin is predictive of patientoutcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
23. P-320 Gefitinib therapy of advanced non small-cell lung cancer (NSCLC): A Markov model-based economic analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.